Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 390,359,424
  • Shares Outstanding, K 2,631,873
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.71
  • Price/Sales 4.76
  • Price/Cash Flow 13.62
  • Price/Book 6.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 2.23
  • Number of Estimates 4
  • High Estimate 2.36
  • Low Estimate 2.10
  • Prior Year 2.10
  • Growth Rate Est. (year over year) +6.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.38 +4.91%
on 01/07/20
150.17 -1.23%
on 01/21/20
+2.39 (+1.64%)
since 12/24/19
3-Month
127.31 +16.50%
on 10/25/19
150.17 -1.23%
on 01/21/20
+20.82 (+16.33%)
since 10/24/19
52-Week
126.10 +17.62%
on 10/24/19
150.17 -1.23%
on 01/21/20
+21.29 (+16.76%)
since 01/24/19

Most Recent Stories

More News
Global Stroke Treatment Market Report 2019-2027 Featuring Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Roche, Johnson & Johnson Services, Sanofi, Amgen, Biogen, and AstraZeneca

The "Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

AMGN : 225.59 (-4.02%)
BMY : 64.16 (-4.05%)
JNJ : 148.32 (-0.14%)
Top Stock Research Reports for Intel, Boeing & Blackstone

Top Stock Research Reports for Intel, Boeing & Blackstone

SRE : 159.76 (-0.19%)
KMI : 21.56 (-0.92%)
JNJ : 148.32 (-0.14%)
INTC : 68.47 (+8.13%)
BX : 62.21 (-2.39%)
BA : 323.05 (+1.66%)
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

MRK : 85.98 (-2.91%)
PFE : 39.82 (-2.19%)
AZN : 49.28 (-1.83%)
RHHBY : 41.2000 (-2.81%)
GSK : 47.23 (-1.23%)
JNJ : 148.32 (-0.14%)
NVS : 93.87 (-1.11%)
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children

Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.

JNJ : 148.32 (-0.14%)
LLY : 139.07 (-1.52%)
BMY : 64.16 (-4.05%)
RHHBY : 41.2000 (-2.81%)
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

JNJ : 148.32 (-0.14%)
The European Commission Approves Expanded Use of Janssen's STELARA(R) (ustekinumab) for the Treatment of Paediatric Patients With Moderate to Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved the expanded use of STELARA(R) (ustekinumab) for the treatment of paediatric patients...

JNJ : 148.32 (-0.14%)
Johnson & Johnson posts higher sales, big 4Q profit jump

Higher prescription drug sales and lower legal costs drove Johnson & Johnson's fourth-quarter profit 32% higher.

JNJ : 148.32 (-0.14%)
Breaking Q4 Earnings News

Breaking Q4 Earnings News

FITB : 28.84 (-1.77%)
JNJ : 148.32 (-0.14%)
ABT : 90.40 (-0.36%)
Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB

Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.

FITB : 28.84 (-1.77%)
JNJ : 148.32 (-0.14%)
ABT : 90.40 (-0.36%)
J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

JNJ : 148.32 (-0.14%)
ABBV : 83.54 (-2.03%)
MRK : 85.98 (-2.91%)
TEVA : 10.10 (-2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 149.41
1st Resistance Point 148.87
Last Price 148.32
1st Support Level 147.85
2nd Support Level 147.38

See More

52-Week High 150.17
Last Price 148.32
Fibonacci 61.8% 140.98
Fibonacci 50% 138.13
Fibonacci 38.2% 135.29
52-Week Low 126.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar